CA2379734C - Treatment of cancers - Google Patents
Treatment of cancers Download PDFInfo
- Publication number
- CA2379734C CA2379734C CA2379734A CA2379734A CA2379734C CA 2379734 C CA2379734 C CA 2379734C CA 2379734 A CA2379734 A CA 2379734A CA 2379734 A CA2379734 A CA 2379734A CA 2379734 C CA2379734 C CA 2379734C
- Authority
- CA
- Canada
- Prior art keywords
- taurolidine
- methylol
- taurultam
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 48
- 238000011282 treatment Methods 0.000 title description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 104
- 238000001802 infusion Methods 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 44
- 238000012546 transfer Methods 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 230000006907 apoptotic process Effects 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 210000004185 liver Anatomy 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 201000007270 liver cancer Diseases 0.000 claims abstract description 6
- 210000005170 neoplastic cell Anatomy 0.000 claims abstract description 5
- 230000002440 hepatic effect Effects 0.000 claims abstract description 4
- 208000037819 metastatic cancer Diseases 0.000 claims abstract 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims abstract 2
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 claims description 111
- 229960004267 taurolidine Drugs 0.000 claims description 106
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 claims description 70
- 229950007343 taurultam Drugs 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 60
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 55
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 31
- RSDQBPGKMDFRHH-MJVIGCOGSA-N (3s,3as,5ar,9bs)-3,5a,9-trimethyl-3a,4,5,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2,6-dione Chemical compound O=C([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 RSDQBPGKMDFRHH-MJVIGCOGSA-N 0.000 claims description 10
- RSDQBPGKMDFRHH-UHFFFAOYSA-N Taurin Natural products C1CC2(C)C(=O)CCC(C)=C2C2C1C(C)C(=O)O2 RSDQBPGKMDFRHH-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical class NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000003501 anti-edematous effect Effects 0.000 claims description 5
- 238000011260 co-administration Methods 0.000 claims description 5
- 239000008151 electrolyte solution Substances 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 210000002767 hepatic artery Anatomy 0.000 claims description 4
- 230000000153 supplemental effect Effects 0.000 claims description 4
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 210000001367 artery Anatomy 0.000 claims description 3
- 150000003672 ureas Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 210000003240 portal vein Anatomy 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 206010018338 Glioma Diseases 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 8
- 239000003792 electrolyte Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000029824 high grade glioma Diseases 0.000 description 5
- 201000011614 malignant glioma Diseases 0.000 description 5
- -1 methylol groups Chemical group 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 208000007774 Broca Aphasia Diseases 0.000 description 4
- 206010017577 Gait disturbance Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008174 sterile solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000005775 apoptotic pathway Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010003062 Apraxia Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIZZEHDLOQDZGP-UHFFFAOYSA-N 2-amino-1-hydroxyethanesulfonic acid Chemical compound NCC(O)S(O)(=O)=O JIZZEHDLOQDZGP-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
- 206010027455 Metastases to kidney Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- BITMAWRCWSHCRW-PFQJHCPISA-N Raffinose Pentahydrate Chemical compound O.O.O.O.O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 BITMAWRCWSHCRW-PFQJHCPISA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- JLMHZVYLAQPMOZ-UHFFFAOYSA-N noxytiolin Chemical compound CNC(=S)NCO JLMHZVYLAQPMOZ-UHFFFAOYSA-N 0.000 description 1
- 229960001194 noxytiolin Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2692295A CA2692295C (en) | 2001-04-03 | 2002-04-02 | Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28074801P | 2001-04-03 | 2001-04-03 | |
| US60/280,748 | 2001-04-03 | ||
| US28171001P | 2001-04-06 | 2001-04-06 | |
| US28171101P | 2001-04-06 | 2001-04-06 | |
| US28171301P | 2001-04-06 | 2001-04-06 | |
| US28171201P | 2001-04-06 | 2001-04-06 | |
| US60/281,710 | 2001-04-06 | ||
| US60/281,713 | 2001-04-06 | ||
| US60/281,712 | 2001-04-06 | ||
| US60/281,711 | 2001-04-06 | ||
| US28493401P | 2001-04-20 | 2001-04-20 | |
| US28493301P | 2001-04-20 | 2001-04-20 | |
| US60/284,934 | 2001-04-20 | ||
| US60/284,933 | 2001-04-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2692295A Division CA2692295C (en) | 2001-04-03 | 2002-04-02 | Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2379734A1 CA2379734A1 (en) | 2002-10-03 |
| CA2379734C true CA2379734C (en) | 2010-06-29 |
Family
ID=27569569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2379734A Expired - Lifetime CA2379734C (en) | 2001-04-03 | 2002-04-02 | Treatment of cancers |
| CA2692295A Expired - Lifetime CA2692295C (en) | 2001-04-03 | 2002-04-02 | Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2692295A Expired - Lifetime CA2692295C (en) | 2001-04-03 | 2002-04-02 | Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030027818A1 (https=) |
| EP (2) | EP2258373B1 (https=) |
| JP (2) | JP2002363102A (https=) |
| CA (2) | CA2379734C (https=) |
| ES (2) | ES2542842T3 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
| US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
| US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US6821968B2 (en) * | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
| US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| EP2353389B1 (en) * | 2003-04-21 | 2015-11-04 | Epeius Biotechnologies Corporation | Compositions for treating disorders |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| CA2482687C (en) * | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| NZ567550A (en) * | 2005-11-29 | 2011-08-26 | Novartis Ag | Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one |
| EP1976531B1 (en) * | 2006-01-06 | 2011-11-09 | Ed. Geistlich Söhne AG für Chemische Industrie | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam |
| US20100040667A1 (en) * | 2006-09-07 | 2010-02-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treating bone cancer |
| CA2801309C (en) * | 2010-06-01 | 2018-07-17 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
| US20170056333A1 (en) * | 2015-08-31 | 2017-03-02 | Cormedix Inc. | Delivery of active agents using nanofiber webs |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| KR20210050544A (ko) * | 2018-08-28 | 2021-05-07 | 코르메딕스, 인코포레이티드 | 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료 |
| EP3843747A4 (en) * | 2018-08-31 | 2022-12-28 | CorMedix Inc. | TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODY |
| US20220323452A1 (en) * | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
| GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
| US5858990A (en) * | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
| DE69828507T2 (de) | 1997-05-20 | 2006-01-05 | Galenica Pharmaceuticals, Inc. | Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung |
| AU734460B2 (en) * | 1997-05-22 | 2001-06-14 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
| GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
| US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| EP1248625A2 (en) | 1999-12-06 | 2002-10-16 | Rhode Island Hospital | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2002
- 2002-03-29 US US10/109,058 patent/US20030027818A1/en not_active Abandoned
- 2002-04-02 CA CA2379734A patent/CA2379734C/en not_active Expired - Lifetime
- 2002-04-02 CA CA2692295A patent/CA2692295C/en not_active Expired - Lifetime
- 2002-04-02 JP JP2002100404A patent/JP2002363102A/ja active Pending
- 2002-04-03 ES ES02252414.4T patent/ES2542842T3/es not_active Expired - Lifetime
- 2002-04-03 ES ES10009649.4T patent/ES2562827T3/es not_active Expired - Lifetime
- 2002-04-03 EP EP10009649.4A patent/EP2258373B1/en not_active Expired - Lifetime
- 2002-04-03 EP EP02252414.4A patent/EP1247524B1/en not_active Expired - Lifetime
-
2009
- 2009-02-03 JP JP2009022892A patent/JP5232678B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2379734A1 (en) | 2002-10-03 |
| EP2258373A1 (en) | 2010-12-08 |
| EP1247524B1 (en) | 2015-06-24 |
| ES2562827T3 (es) | 2016-03-08 |
| ES2542842T3 (es) | 2015-08-12 |
| JP2002363102A (ja) | 2002-12-18 |
| JP2009138003A (ja) | 2009-06-25 |
| JP5232678B2 (ja) | 2013-07-10 |
| CA2692295C (en) | 2013-06-25 |
| EP2258373B1 (en) | 2016-01-27 |
| US20030027818A1 (en) | 2003-02-06 |
| CA2692295A1 (en) | 2002-10-03 |
| EP1247524A1 (en) | 2002-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2379734C (en) | Treatment of cancers | |
| US6693125B2 (en) | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | |
| US7638511B2 (en) | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) | |
| JP2020079259A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| EP3452042A1 (en) | Systems and methods for treating bacterial infection | |
| US20030092707A1 (en) | Treatment of breast cancer | |
| CA2482687C (en) | Treatment of mesothelioma | |
| US20050096314A1 (en) | Treatment of cancers with methylol-containing compounds and at least one electrolyte | |
| US20080171738A1 (en) | Treatment of Breast Cancer | |
| US8030301B2 (en) | Treatment of cancers with methylol-containing compounds and at least one electrolyte | |
| US20050124608A1 (en) | Treatment of cancers | |
| US20070275955A1 (en) | Method of treating tumors | |
| AU2002252338B2 (en) | Taurine compounds | |
| US7928102B2 (en) | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam | |
| WO2007020509A1 (en) | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth | |
| US8304390B2 (en) | Method of treatment for preventing or reducing tumor growth in the liver of patient | |
| US20060199811A1 (en) | Method of treatment for preventing or reducing tumor growth in the liver of patient | |
| Mattie | Efficacy and nephrotoxicity of aminoglycosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220404 |